Allopurinol and Endothelial Function in Diabetic CAD Patients
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized trial assessing the impact of allopurinol on endothelial function in
optimally treated diabetic patients with coronary artery disease. After initial screening,
subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT
alone for 8 weeks. The dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with
a 4-weekly check on hematology and biochemistry